NGM’s Pan-FGF Receptor Approach In NASH Shows Benefits And Drawbacks

24 Feb 2020

NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.

Graphic Move On Forward Icon Concept — NGM's aldafermin shows strong data in Phase II, moves closer to pivotal study

NGM Biopharmaceuticals Inc.’s FGF19 analog aldafermin became the first drug candidate to achieve statistical significance on the composite endpoint of resolving non-alcoholic steatohepatitis (NASH) and improving fibrosis in NASH patients. The firm said the drug’s mechanism of action, while increasing LDL cholesterol, also produces a broader benefit than other NASH drugs have demonstrated.

NGM reported on 24 February that the fourth cohort of its adaptable Phase II study in NASH patients with fibrosis...